BidaskClub upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a buy rating to a strong-buy rating in a research note published on Monday.

A number of other research analysts have also weighed in on the stock. HC Wainwright boosted their target price on shares of Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a buy rating in a research report on Tuesday, January 16th. William Blair initiated coverage on shares of Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They set an outperform rating for the company. Finally, ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, December 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $10.00.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at $7.15 on Monday. Pieris Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $8.58.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $3.93 million during the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The company’s quarterly revenue was up 400.3% on a year-over-year basis. equities analysts predict that Pieris Pharmaceuticals will post -0.62 earnings per share for the current year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.05% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in PIRS. State Street Corp acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $2,377,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $1,625,000. TIAA CREF Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $649,000. Vanguard Group Inc. acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $526,000. Finally, Strs Ohio raised its position in shares of Pieris Pharmaceuticals by 1,028.0% during the fourth quarter. Strs Ohio now owns 112,800 shares of the biotechnology company’s stock valued at $851,000 after buying an additional 102,800 shares during the last quarter. 50.78% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/bidaskclub-upgrades-pieris-pharmaceuticals-pirs-to-strong-buy/1854455.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.